Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary sclerosing cholangitis

E J Esber1, D R Ferguson

  • 1MetroHealth Medical Center, Cleveland, OH.

The Gastroenterologist
|June 1, 1994
PubMed
Summary
This summary is machine-generated.

Primary sclerosing cholangitis (PSC) is a liver disease with unknown causes, often linked to inflammatory bowel disease (IBD). Research explores its immune system links and identifies treatments, with liver transplantation as a last resort.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Afternoon colonoscopies have higher failure rates than morning colonoscopies.

The American journal of gastroenterology·2007
Same author

Use of tegaserod along with polyethylene glycol electrolyte solution for colonoscopy bowel preparation: a prospective, randomized, double-blind, placebo-controlled study.

Alimentary pharmacology & therapeutics·2006
Same author

Improving compliance with postpolypectomy surveillance guidelines: an interventional study using a continuous quality improvement initiative.

Gastrointestinal endoscopy·2005
Same author

P2X and P2X receptor expression in human bladder urothelium and changes in interstitial cystitis.

BJU international·2004
Same author

Distribution of P2X(1) and P2X(3) receptors in the rat and human urinary bladder.

Pharmacology·2001
Same author

Direct toxicity of nonsteroidal antiinflammatory drugs for renal medullary cells.

Proceedings of the National Academy of Sciences of the United States of America·2001
Same journal

Update on obesity treatment.

The Gastroenterologist·1998
Same journal

Pathophysiology and treatment of hepatorenal syndrome.

The Gastroenterologist·1998
Same journal

Common pediatric esophageal disorders.

The Gastroenterologist·1998
Same journal

The technical aspects of biofeedback therapy for defecation disorders.

The Gastroenterologist·1998
Same journal

Magnetic resonance cholangiopancreatography: a new technique for evaluating the biliary tract and pancreatic duct.

The Gastroenterologist·1998
Same journal

Fecal occult blood testing: clinical value and limitations.

The Gastroenterologist·1998
See all related articles

Area of Science:

  • Hepatology
  • Immunology
  • Gastroenterology

Background:

  • Primary sclerosing cholangitis (PSC) is a chronic liver disease with an unknown cause.
  • PSC is frequently associated with inflammatory bowel disease (IBD), particularly ulcerative colitis (UC).
  • Potential causes like copper overload and bacterial infections have been largely excluded, with ongoing research into viral factors (Cytomegalovirus, reovirus) and genetic predispositions (familial clustering, HLA subtypes).

Purpose of the Study:

  • To review the current understanding of Primary Sclerosing Cholangitis (PSC) etiology, pathogenesis, clinical features, diagnosis, and treatment.
  • To highlight the immunological aspects suggested by the presence of antineutrophil cytoplasmic antibodies (ANCA) in PSC and UC patients.
  • To discuss the role of diagnostic imaging and therapeutic interventions, including symptomatic management, experimental treatments, and liver transplantation.

Related Experiment Videos

Main Methods:

  • Review of existing literature and patient data on Primary Sclerosing Cholangitis (PSC).
  • Analysis of diagnostic techniques such as Endoscopic Retrograde Cholangiopancreatography (ERCP) and Percutaneous Transhepatic Cholangiography (PTC).
  • Evaluation of various treatment modalities, from symptomatic relief to experimental therapies and liver transplantation.

Main Results:

  • The etiology of PSC remains unknown, but strong associations with IBD and potential immune system involvement (ANCA) are noted.
  • Diagnostic imaging (ERCP, PTC) aids in characterizing PSC and guiding interventions.
  • Treatment strategies include symptomatic management, experimental drugs (D-penicillamine, UDCA, methotrexate, corticosteroids), and ultimately liver transplantation for advanced disease.

Conclusions:

  • PSC is a complex liver disease requiring further etiological research, with significant links to IBD and immunological factors.
  • Effective diagnosis and management involve advanced imaging and a multi-faceted treatment approach, including transplantation for end-stage cases.
  • PSC represents a significant medical and economic burden, necessitating continued research for improved patient outcomes and quality of life.